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INTRODUCTION 
Antimony is an element belonging to group 15 in period table and having an atomic 
number 51. Since it has both physico-chemical properties of typical element and metal, 
it is called a metalloid. Antimony and its compounds and alloys are industrially useful 
e.g., lead batteries, solder, flame retardants, textiles, paper, etc. Trivalent antimony is 
more abundant in the earth under anaerobic condition than pentavalent one, and more 
widely used as a rare earth element in human activities. (Sundar and Chakravarty, 2010). 
With the increase in the industrial applications, the risk of antimony exposure could be 
increased. Antimony and antimony compounds have been recognized as a non-essential 
and a toxic metalloid and their carcinogenicity is classified as the group 2B by IARC, 
meaning that it has sufficient carcinogenic potential for animals, and its carcinogenicity 
to humans is unknown. US Environmental Protection Agency listed antimony as an 
environmental pollutant in 1976. Therefore, the United States, Germany, the European 
Union, Japan, and the World Health Organization have all stipulated antimony 
concentration in drinking water. The sources of antimony in the environment are not 
common. In the United States, Japan, Germany and some other countries, antimony 
dust pollution in the atmosphere due to flame retardant is mainly generated (He et al., 
2018). China is the largest antimony reserving and antimony producing country in the 
world. China has produced about 80% of the total antimony production. Antimony mine 
is mainly located in Guangxi Province, Hunan Province, Yunnan Province and Guizhou 
Province. The residents in these areas suffer from air pollution and water contamination 
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of antimony from the mine. Actually the antimony air pollution seriously threatens the 
health of surrounding residents (He et al., 2012; Ye et al., 2018).   
As the other side of antimony, it is used in clinical. Leishmaniasis is a zoonotic 
disease caused by Leishmania spp. and is transmitted among mammals through 
sandflies. When the infected sandfly bites a person, promastigotes are injected into the 
subcutaneous tissue. The promastigotes are incorporated into macrophages by 
phagocytosis, and grow up and reproduce in macrophage (Sundar and Goyal, 2007). It 
is estimated that the disease is endemic in 98 countries of Asia, Africa, and Southern 
Europe, with approximately 2 million new cases each year (Mishra M, Biswas UK, Jha 
DN, 1992). The clinical manifestations of leishmaniasis caused by different species are 
different, and can be divided into visceral leishmaniasis (VL), cutaneous leishmaniasis 
(CL) and mucocutaneous leishmaniasis (ML). CL causes severe damages to the 
appearance of patient, and VL is fatal if the patient is left without any treatments. 
Antimony compounds have been used as a clinical agent for the treatment of 
leishmaniasis for more than 70 years. Meglumine antimonate and sodium 
stibogluconate named Glucantime and Pentostam in the market, respectively, have a 
strong insecticidal effect on leishmania. These compounds contain pentavalent 
antimony (Sb(V)), and pentavalent antimony is reduced to trivalent antimony (Sb(III)) 
in the parasite bodies (Decuypere et al., 2005). Although the molecular and cellular 
mechanisms underlying the anti-parasitic effect of antimony are not fully understood, 
some mechanisms have been proposed mentioned below. Trypanothione (T(SH)2) 
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consisting of glutathione (GSH) and spermidine is a unique thiol compound in 
Leishmania, and has the function reducing Sb(V) to Sb(III). Trypanothione reductase 
(TR) is a potential molecular target for Sb (III) (Haldar et al., 2011). Sb(III) hampers 
the redox potential of Leishmania by inducing thiol efflux and inhibiting NADPH-
dependent TR. Leishmania obtains the resistance against Sb(III) through multiple 
pathways, for example, the introduction of mutations in AQP1 which is am importer of 
Sb(III) or the induction of genes involving in the parasite thiol metabolism (Gazanion 
et al., 2019; Sundar and Goyal, 2007). The tolerant leishmaniasis against the Sb 
treatment are often reported in the areas with frequent Leishmaniasis infections and the 
patients with relapses of leishmaniasis. In those area, the cure rate of antimony 
treatment was decreased in the recent years (Croft et al., 2006). In the recent years, a 
variety of drug-resistant strains have been found clinically. Increasing the dose of 
medicine can increase the cure rate and shorten the treatment period, however, the side 
effects of the medicine based on the antimony toxicity have to be considered. The main 
side effects of antimony treatment are fever, cough, nausea, diarrhea, and abdominal 
pain. The drug resistance is now one of important issues in the treatment of 
leishmaniasis. It is necessary to know the toxicological mechanisms of antimony to 
overcome the antimony resistance in leishmaniasis.  
Arsenic is one of serious environmental contaminants in the world. Arsenic and 
arsenic compounds are classified as group 1, primary carcinogens by IARC, 
carcinogenicity is determined for animals, and it is also carcinogenic to humans. On the 
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other hand, arsenic trioxide is used as a medicine to treat acute myeloblastic leukemia. 
Arsenic having atomic number 33 is the same group as antimony in the period table, 
and has similar physical and chemical properties to antimony. As the unique arsenic 
toxicity, species differences are known. Among the rodents, rats are highly tolerant to 
arsenic while hamsters are susceptible (Naranmandura et al., 2007). The important 
metabolism of arsenic is that inorganic arsenic is methylated to mono- and dimethylated 
arsenicals. The methylation of arsenic in mammals is accomplished by arsenic (III) 
methyltransferase (AS3MT). In addition, inorganic arsenic is conjugated with GSH, 
and the conjugate, As (GS)3, is excreted (Hayakawa et al., 2005; Naranmandura et al., 
2006).  
It can be speculated that if the antimony is biologically and toxicologically similar 
to arsenic, then antimony toxicity may also be species differences, and in vivo 
metabolism of antimony may also be metabolized by methylation in combination with 
GSH. In this study, in order to verify the antimony toxicity species differences, 
differences in antimony metabolic concentrations in blood and urine of rats and 
hamsters were evaluated. In in vitro experiments, human embryonic kidney cells 
(HEK293), were used to reveal the mechanisms for the cytotoxicity of inorganic 
trivalent antimony. The drug resistance and adverse effect of antimony were also 
discussed. 
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I. SPECIES DIFFERENCES IN ANTIMONY TOXICITY 
Materials and Methods 
Chemicals  
Potassium antimony tartrate (Sb(III)), potassium hexahydroxoantimonate (V) 
(Sb(V)), nitric acid, hydrogen peroxide, ammonium acetate, and nitric acid for metal 
analysis were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
Saline was purchased from Otsuka Pharmaceutical Factory (Tokushima, Japan). 
Antimony (Sb) standard solutions and arsenic (As) standard solution was purchased 
from Nacalai Tesque (Kyoto, Japan). 
 
Instruments  
Conical centrifuge tubes were purchased from Thermo scientific (NY, USA). 
Centrifuge 2700 was purchased from KUBODA Laboratory Centrifuges Japan 
(Tokyo, Japan). ICP–tandem mass spectrometer (ICP–MS/MS Agilent 8800) was 
purchased from Agilent (CA, USA). 
 
Animals 
All animal experiments were carried out according to the Principles of Laboratory 
Animal Care (NIH version, revised 1996) and the Guidelines of the Animal 
Investigation Committee, Chiba University, Japan (28-60, 28/01/2016).  
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Specific pathogen free (SPF) male Wister rats and Syrian hamsters (5 weeks of age) 
were purchased from Japan SLC (Shizuoka, Japan) and were housed in a humidity-
controlled room maintained at 25 ± 2 ◦C with a 12 h light-dark cycle. The rats and 
hamsters were fed a commercial diet (MF, Oriental Yeast Co., Ltd., Tokyo, Japan) and 
tap water ad libitum. 
 
Preparation for Sb(III) and Sb(V) solution  
A 0.2 g portion of potassium antimony tartrate powder or a 0.5 g portion of 
potassium hexahydroxo antimonate (V) was added into 10 ml of degassed Milli-Q. 
Then, they were stirred and dissolved under argon atmosphere for 10 minutes. 
 
Determination of Sb concentration by ICP-MS 
The concentrations of Sb(III) solution and Sb(V) solution were determined by ICP-
MS with a standard calibration method. Signal intensities of Sb was monitored at m/z 
121. Sb(III) solution at a concentration of 35.95 mg/ml and Sb(V) solution at a 
concentration of 12.14 mg/ml served as stock solution. These solution were diluted 
prior to use. 
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Oral administration of Sb compounds to Rats and Hamsters 
After a one-week acclimation period, their drinking water was changed from tap 
water to Milli-Q water (18.3 MΩ cm). The animals fed the commercial diet and Milli-
Q water for 1 day. Four rats or hamsters per group (n=4) were orally administered 
antimony (dissolved in physiological saline 5 mg Sb/kg body weight), and the animals 
were euthanized at 1 day after administration. control group were administered the 
same volume of physiological saline (10 mL/kg). The animals were housed in a 
metabolic cage to collect urine for 24 h. 
 
Sample preparation of blood and urine 
Blood samples were obtained from abdominal aorta. Hematocrit value was measured 
by hematocrit capillary. A 500 μL whole blood was mixed with 500 μL of concentrated 
nitric acid in a test tube, and the mixture was ashed at 200℃ for 1 day until the solution 
became colorless. Remained heparinized whole blood was collected and centrifuged at 
1600×g for 10 min to separate serum and red blood cells (RBCs). 
A 500 μL aliquot of the collected urine, a 100 μL serum were mixed with 500 μL of 
concentrated nitric acid in a test tube respectly, and the mixture was ashed at 200℃ for 
1 day until the solution became colorless. Remaining serum, RBCs, and urine were 
stored at -80℃. 
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Sample preparation of organs 
Brains, lungs, livers, kidneys and testes were excised, and frozen in liquid nitrogen. 
A 0.1g portion of each organ was ashed with 500μL of concentrated nitric acid in a test 
tube, and heated at 200℃ for 1 day until the solution became colorless. 
 
Determination of elements by ICP-MS 
The concentrations of Sb and arsenic in the samples were determined by ICP-MS 
with a standard calibration method. Signal intensities of Sb and arsenic were monitored 
at m/z 121 and 75, respectively. 
 
Statistical analysis 
All determinations were performed in four replicates and the results are shown as 
means ± S.D. Statistical analysis was conducted by applying the two-way analysis of 
variance (ANOVA) with Bonferroni’s multiple comparisons test. 
 
Results 
Arsenic concentration in blood 
The arsenic concentration in whole blood of rats was much higher than that of 
hamsters (Fig 1a). The arsenic concentration in whole blood was significantly 
decreased by the administration of Sb(III) or Sb(V).There was no significant difference 
in arsenic accumulation in plasma of the rats and hamsters (Fig 1b).Due to the large 
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difference between rat and hamsters, the Y-axis in Fig. 1a and 1c was shown in a 
logarithmic scale. The arsenic concentration in RBC was also significantly decreased 
by the administration of Sb(III) or Sb(V). 
The administration of Sb(V) more preferably induced the accumulation of arsenic 
on RBC than Sb(III) (Fig. 1c). 
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Fig. 1. Arsenic concentrations in whole blood (a), plasma (b), and red blood cells (c) 
of Wistar rat and Syrian hamster orally administered Sb(III) and Sb(V). Data are 
expressed as means ± S.D. of 4 samples. # indicates significant difference between 
control and Sb-treated groups at p<0.05. * indicates significant difference between rat 
and hamster groups at p<0.05. 
 
Antimony concentration in blood 
After antimony treatment, the concentration of antimony in whole blood of rats was 
higher than that of hamster whole blood (Fig 2a). Sb(III) was more preferably 
accumulated in whole blood of rats than Sb(V). Although Sb was not accumulated in 
the plasma of rats, it was accumulated in the plasma of hamster. 
Sb was also more preferably accumulated in rat RBC than hamster RBC like arsenic. 
However, arsenic was more severely accumulated than Sb. 
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Fig. 2. Antimony concentrations in whole blood (a), plasma (b), and red blood cells (c) 
of Wistar rat and Syrian hamster orally Sb(III) and Sb(V). Data are expressed as means 
± S.D. of 4 samples. * indicates significant difference between rat and hamster groups 
at p<0.05. † indicates significant difference between Sb(III)- and Sb(V)-treated groups 
at p<0.05. 
 
Antimony concentration in urine 
There were no significant differences between the rats and hamsters in the amount 
of Sb in the urine collected for 24 h after the Sb administration. (Fig 3). There were no 
apparent differences between Sb(III) and Sb(V) in the amount of Sb in the urine. 
 
Fig. 3. Antimony levels in urine of Wistar rat and Syrian hamster orally administered 
Sb(III) and Sb(V). Data are expressed as means ± S.D. of 4 samples. * indicates a 
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significant difference between rat and hamster groups at p<0.05. † indicates a 
significant difference between Sb(III)- and Sb(V)-treated groups at p<0.05. 
 
Arsenic concentration in urine 
The amount arsenic in the urine of the rat control group was significantly higher than 
that of the hamster control group. The amount of arsenic in the control rat urine was 
decreased by the administration of Sb(III) and Sb(V). The arsenic amount in the urine 
of the experimental group was not significantly different between rats and hamsters 
(Fig 4). 
 
Fig. 4. Arsenic levels in urine of Wistar rat and Syrian hamster orally administered 
Sb(III) and Sb(V). Data are expressed as means ± S.D. of 4 samples. # indicates 
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significant difference between control and Sb-treated groups at p<0.05. * indicates 
significant difference between rat and hamster groups at p<0.05. 
 
Antimony concentration in organs 
In the brain, lung, liver, and kidney after orally administered Sb(Ⅲ) for 24 h, the 
concentration of antimony was significantly increased both in rats and hamsters. 
Antimony concentration in the brain of Sb(Ⅴ) group hamster was were significantly 
higher than that in the rat brains (Fig.5a). The concentration of antimony in the lung of 
Sb(Ⅲ) group rat was significantly higher than that in hamster lungs (Fig.5b). As shown 
in Fig.5c, compared with the control group, after the orally administration of  Sb(Ⅴ), 
the concentration of antimony in the hamster livers was increased, but the concentration 
of the rat livers was not. The same result was found in the kidneys (Fig.5d). In the testis, 
antimony concentration in the Sb(Ⅲ) group were not significantly increased than 
control group both in the rats and hamsters. Antimony concentration in hamster the 
Sb(Ⅴ) group was significantly increased than the control (Fig.5e). 
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Fig. 5. Sb concentration in Wista rats and Syrian hamsters organs after the Sb(Ⅲ) and 
Sb(Ⅴ) orally administration. a: brain; b: lung; c: liver; d: kidney; e: testis. Data are 
expressed as the mean standard deviation (n= 4). # indicates a significant difference 
from control. * indicates a significant difference from rat to hamster. † indicates a 
significant from the Sb(Ⅲ) group to the Sb(Ⅴ) group. 
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Arsenic concentration in organs 
Arsenic concentrations in rat brain, lung, liver, and kidney were higher than those in 
hamsters (Fig.6a-d). The arsenic concentration in the testis seemed no differences 
between rat and hamster. With the oral administration of Sb, arsenic concentrations in 
organs have no changes both in rats and hamsters. 
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Fig. 6. As concentration in the organs of Wista rats and Syrian hamster organs after the 
Sb(Ⅲ) and Sb(Ⅴ) orally administration. a: brain; b: lung; c: liver; d: kidney; e: testis. 
Data are expressed as the mean standard deviation (n= 4). # indicates a significant 
difference from control. * indicates a significant difference from rat to hamster. † 
indicates a significant from Sb(Ⅲ) group to Sb(Ⅴ) group 
 
Discussion 
The results indicate that inorganic antimony is more preferably accumulated in rat 
RBCs rather than hamster RBCs. The arsenic content derived from commercial diet 
and tap water in the whole blood, especially blood cells, of rats. These observations 
confirm the species difference in arsenic metabolism between rat and hamster, and are 
in agreement with a previous report (Naranmandura et al., 2007; Shiobara et al., 2001). 
According to previous studies, Rat hemoglobin 𝛼 chain and 𝛽 chain have a unique 
amino acid sequence, namely, there is a specific cysteine residue on its sequence that 
binds arsenic(Lu et al., 2004). After trivalent antimony and pentavalent antimony were 
administered to rats, the arsenic accumulation in whole blood and blood cells decreased 
by 30%. This result shows that in the blood cells of rats, antimony competes with 
arsenic. Antimony may also bind to the special structure of hemoglobin and accumulate 
in rat blood. No accumulation of antimony occurred in hamster whole blood and RBCs. 
A small amount of antimony accumulated in the hamster's plasma, and the part that did 
not accumulate in the RBCs tended to accumulate in the plasma. 
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After oral administration of trivalent antimony and pentavalent antimony, the 
amount of arsenic excretion in rats decreased, which may be caused by the competitive 
relationship between arsenic and antimony in the renal tubules of rats. 
The results of organs indicated arsenic and antimony have no competitive 
relationship in the organs both in the rat and hamster. There indicated that the amount 
of Sb distributed to each organ were within the metabolic capacity of arsenic. To reveal 
the molecular mechanisms underlying the Sb metabolism, the cultured cell were used 
in the next section. 
Due to the highly tolerant of rat to arsenic toxicity, it is an inappropriate animal 
model for studies of arsenic toxicity. Previous study shows that inorganic trivalent 
antimony has a strong affinity for RBCs (Mengchang, 2005). However, the results of 
this study confirmed that although inorganic trivalent antimony does have a strong 
affinity with the RBCs of rats, it does not have the RBCs of hamsters. In the safety 
evaluation experiment of antimony-containing leishmaniasis medicine research, and in 
the antimony toxicity test, it is necessary to consider the resistance of the experimental 
animals to antimony.  
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II. MOLECULAR MECHANISMS FOR ANTIMONY TRANSPORT 
Materials and Methods 
Chemicals  
Potassium antimony tartrate (Sb(III)), potassium hexahydroxoantimonate (V) (Sb(V)), 
glutathione reduced form (GSH), nitric acid, hydrogen peroxide, ammonium acetate, 
nitric acid for metal analysis, ISOGEN II, agarose S, Gene Ladder Fast 2 (6 
bands:0.1-10 kbp), 0.25w/v% Trypsin-1mmol/l EDTA·4Na solution with phenol red 
(PET), penicillin-streptomycin (PS) and 1% non-essential amino acid (NEAA) were 
purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). SYBR safe 
DNA gel stain was purchased from Invitrogen by Thermo Fisher Scientific (MA, 
USA). Fetal bovine serum (FBS) was purchased from Biosera (Nuaille, France). 
Minimum Essential Medium Eagle (MEME), phosphate buffered saline (PBS), and 
buthionine sulfoximine (BSO) were purchased from Sigma-Aldrich (St. Louis, USA). 
ReverTra Ace® qPCR RT Master Mix was purchased from TOYOBO (Tokyo, 
Japan). TaKaRa Ex Taq was purchased from TAKARA BIO, INC (Shiga, Japan). 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was purchased 
from Promega (Madison, USA). Antimony (Sb) standard solutions and loading dye 
brilliant color (6x) were purchased from Nacalai Tesque (Kyoto, Japan). 
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Instruments  
Conical centrifuge tubes and cell culture plates were purchased from Thermo 
scientific (NY, USA). Centrifuge 2700 was purchased from KUBODA Laboratory 
Centrifuges Japan (Tokyo, Japan). ICP–tandem mass spectrometer (ICP–MS/MS 
Agilent 8800) was purchased from Agilent (CA, USA). Spectrophotometer U-3900H 
was purchased from HITACHI (Tokyo, Japan). T100 Thermal Cycler was purchased 
from BIO-RAD (CA, USA). ImageQuant LAS 4000 was purchased from GE Health 
Care Life Science (Tokyo, Japan). Sealed decomposition vessel was purchased from 
San-ai Kagaku co. ltd (Aichi, Japan). Stackable incubator shaker was purchased from 
Waken Btech (Kyoto, Japan). High speed refrigerator micro centrifuge was purchased 
from Kitman (Tomy, Tokyo, Japan). Filtermax F5 multi-mode microplate reader and 
Emax precision microplate reader was purchased from Molecular Devices (CA, USA). 
PRP-X100 column, 10 μm, 150× 4.1 mm, was purchased from Hamilton (Nevada, 
USA). 
 
Cells 
Human embryonic kidney 293 (HEK293) cells were purchased from RIKRN Cell 
Bank (Ibaraki, Japan). The HEK-293 cells were maintained in MEME supplemented 
with 10% Fetal Bovine Serum （FBS）, 1% non-essential amino acids （NEAA）, 
and 1% Penicillin-Streptomycin （PS） at 37℃ under 5% CO2 atmosphere.  
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Gene primers 
The primers of ABCC1, ABCC2, MDR1, SLC4A1, SLC34A2, AQP7, and GAPDH 
primers were purchased from SIGMA-Aldrich (St. Louis, USA). The sequences of 
primers are shown in Table. 1. 
Table 1. Sequences of primers used in this study 
Gene Forward primer Reverse primer 
hABCC1 5’ACCCTAATCCCTGCCCAGAG3’ 5’CGCATTCCTTCTTCCAGTTC3’ 
hABCC2 5’AGGATGACATCAGAAATAGAGACC3’ 5’CTACTCCATCAATGATAATCTGAC3’ 
hMDR1 5’CAGGAACCTGTATTGTTTGCCACCAC3’ 5’TGCTTCTGCCCACCACTCAACTG3’ 
hAQP7 5’GTGATAGGCATCCTCGTGGT3’ 5’TAGGCACCCAGAGTGGTG3’ 
hGAPDH 5’GCACCGTCAAGGCTGAGAAC3’ 5’TGGTGAAGACCGCCAGTGGA3’ 
Cell culture and Sb exposure 
HEK293 cells were grown and maintained in MEME supplemented with 10% FBS, 
1% NEAA, and 1% PS at 37℃ under 5% CO2 atmosphere. HEK293 cells were seeded 
at a density 1×105 cells per dish into the 6-cm cell culture dish and the cells were used 
at 70 - 80% confluence for experiments. 
The cells were exposed the cells with 30 μM Sb(III) for 24 h. A control group was 
exposed with the same volume of PBS. 
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Isolation of total RNA 
Total RNA was extracted from HEK293 cells using ISOGEN II following the 
manufacturer’s instruction. The protocol is as follows: 
A portion of 0.5 mL ISOGENⅡ and a portion of 0.2 mL RNase free water were 
added in the 6-cm dishes which contain cell samples (cells: about 2.5×106 cells), then 
the mixtures moved to microcentrifuge tubes and mixed by vigorously shaking for 15 
sec. After allowed to stand at room temperature for 10 min, the mixtures were 
centrifuged for 15 min. The supernatants were mixed with a portion of 1 mL 
Isopropanol by inversion, then allowed to stand at room temperature for 10 min, and 
then centrifuged for 10 min. The precipitates were added with 150 μL 75% ethanol, 
then centrifuged at 1200 rpm 4℃ for 10 min, twice. The precipitates were added with 
RNase free water to obtain total RNA solutions. 
RNA determination by RT-PCR 
Total RNA was reverse transcribed to cDNA by ReverTra Ace® qPCR RT Master 
Mix following the manufacturer’s instruction whereas PCR were using T100 Thermal 
Cycler.  
The reation mixture was incubate at 37°C for 15 min, then intubated at 50°C for 5 
min, and heated at 98°C for 5 min. The cDNA were used for the following PCR. 
The cDNA general reaction mixture for PCR consisted of 1.5 μL buffer tax, 1.2 μL 
dNTPs, 0.1 μL Forward Primer, 0.1 μL Reverse Primer, 1.0 μL cDNA , 10.92 μL H2O 
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and 0.08 μL Taq polymerase . For the PCR, 1 cycle of denaturation (95 °C for 180 s), 
34 cycles of denaturation (95 °C for 10 s), 34 cycles of annealing the specific 
temperature to each gene for 15 s and elongation (72 °C for 15 s) were performed 
using the primer pairs shown in Table. 1. The specific annealing temperatures were 
follows: hABCC1 63℃; hABCC2 55℃; hMDR1 59℃; hAQP7 65℃; hGAPDH 
63℃. 
The PCR products were loaded in 2% agarose gel and the electrophoresis was 
conducted in Tris-acetate-EDTA (TAE) buffer on 80 mV for 1 h. The gel was put into 
a 10,000-fold diluted SYBR Safe solution and allowed to stand for 15 minutes under 
light-shielding conditions for staining. 
Color rendering by ImageQuant LAS 4000 at absorbs blue light (λmax = 509 nm) 
and emits green light (λmax = 524 nm). ImageJ program was used to compare the 
fluorescence brightness of each transporter gene with the expression of housekeeping 
gene, GAPDH. 
 
BSO exposure and GSH determination 
BSO was dissolved by PBS and diluted by potassium phosphate buffer with 1 mM 
EDTA. HEK293 cells were seeded on 15-cm dish, until 70-80% confluence. The cells 
were exposed to 25 μM BSO for 24 h. The cells in PBS as a control. The cells were 
washed twice with PBS, and collected with trypsin/EDTA. The collected cells were 
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washed with PBS and counted with a counting chamber, and then added PBS to make 
the cell concentration of 1.2 × 107 cells / 500 μL.  
All the suspension was centrifuged at 500 × g for 10 min at 4°C. The cell pellet was 
dissolved with 100 mmol/L hydrochloric acid, and frozen/ thawed in liquid nitrogen. 
And then ultrasonicated for 5 min. The reactant was added with 5% 5-Sulfosalicylic 
Acid Dihydrate (SSA) solution and centrifuged at 10,000×g for 10 min. The 
supernatant was diluted 10-fold with potassium phosphate buffer, and the control 
groups was diluted 100-fold. 
GSH powder was dissolved by SSA solution, and then diluted by potassium 
phosphate buffer with 1 mM EDTA to obtain GSH standard solution. The 
concentrations of GSH Standard were 3.13 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM. The 
GSH concentration was measured protocol as follows: 
A portion of 50 μL/well sample or standard solution were added to 96 well plate. 
After a 50 μL portion of 500 μM DTNB solution and a portion of 50mU GR solution 
were added to the plate, incubated mixture at 37℃ for 3min. Then, a 50 μL portion of 
500 μM NADPH solution was added to the plate. The samples and standards were 
measured at 405 nm absorbance interval 30 seconds. 
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Evaluation of Sb toxicity in HEK293 cells  
HEK293 cells were seeded at a density 1×104 cells per well into two 96-well flat-
bottom plates. At 70-80% confluence, the cells in one plate was exposed with 25 μM 
BSO for 24 h, whereas the cells in the other plate was exposed with PBS as control. 
Then, the cells were exposed with 1 μM, 10 μM, 100 μM, 200 μM, 500 μM, 1000 μM, 
2000 μM, and 5000 μM of Sb(III) for 24 h. The cells were added with 20 μL/well of 
CellTiter 96, and then, incubated for 1 h. The cell viability was determined by 
absorbance at 490 nm. 
 
Determination of Sb concentration in HEK293 cells by ICP-MS 
HEK293 cells were seeded at a density 1×107 cells/ well on 15-cm plates. At 70-80% 
confluence, the cells in one plate was exposed with 25 μM BSO for 24 h, whereas the 
cells in the other plates were exposed with PBS or MEME as control. Then, the cells 
were exposed with 100 μM Sb(III) solution for 24 h.  
After 24 h the cells were washed with PBS twice, and collected with trypsin/EDTA. 
After counted the cell number by a counting chamber, the cells were suspended in PBS 
and transferred to sealed decomposition vessel. The cell suspension in the inner bottle 
was placed on a 100°C hot plate until dried up. A 1 mL 60% nitric acid into an inner 
bottle and added a 1 mL portion of 1 M NaOH was added into outer bottle. A PTFE 
cap was put onto the bottle and placed into a cylinder. A hand tightening was used to 
close the vessel with a screw cap. A torque wrench with a recommended torque was 
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used to close the vessel completely. The bottle was put in a microwave oven and heated 
it at 350 W for 2 min. The vessel was allowed down to room temperature. The center 
screw anticlockwise was turned before loosening the screw cap. Removed the screw 
cap and took the PTFE bottle by pushing up the bottom plate inside the cylinder to 
obtain samples. 
The antimony concentration in the cells were determined by ICP-MS with a standard 
calibration method. The signal intensities of Sb were monitored at m/z 121. 
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Evaluation of Antimony methylation 
Reaction mixtures consisted according to the following recipe (Table 2): 
Table 2. Composition of reaction mixture 
 
Sample 
(μL) 
Negative 
(μL) 
Final 
concentration 
1mM As(III) or Sb(III) 0.5 0.5 1.0 μM 
482 μg/mL AS3MT 100 — 100 μg/mL 
100 mM GSH 50 50 10 mM 
32 mM SAM 15 15 1.0 mM 
200 mM sodium 
phosphate buffer 40 50 20 mM 
Milli-Q 294.5 384.5  
Total 500 500  
 
The reaction mixture was incubated at 37°C for 4 h, then heated at 95 ° C for 5 min. 
A 500 μL portion of 6% H2O2, was added to reacted at 130 rpm 37 ° C for 1 h by a 
stackable incubator shaker. The mixture was added with catalase until no bubbles, and 
centrifuged at 13,000 × g 4° C for 5 min. The supernatant was filtered by a 0.45 μm 
filter. 
Antimony speciation in the reaction mixture was performed by LC-ICP-MS. The 
column PRP-X100 was eluted with 50 mM ammonium acetate, pH 6.5, at the flow rate 
of 0.8 mL/min. A 50µL aliquot of the reaction mixture was applied to the column, and 
the signal intensity of antimony was monitored at m/z 121. 
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Statistical analysis 
All determinations were performed in four replicates, and the results are shown as 
means ± S.D. Statistical analysis was conducted by applying the one-way analysis of 
variance (ANOVA) with Bonferroni’s multiple comparisons test. 
 
Result 
Responses of gene expression to Sb exposure 
The results are shown in Fig 7. The expressions of ABCC1, ABCC2, and MDR1 
transporter genes showed a tendency to be increased with the Sb exposure, and only the 
elevated level of ABCC2 were statistically significant under the statistical analysis. The 
AQP7 expression level was reduced with the Sb exposure but the reduction was not 
statistically significant. 
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Fig. 7. Effect of Sb exposure on gene expressions of ABCC1 (a), ABCC2 (b), MDR1 (c), and AQP7 
(d). Data are expressed as means ± S.D. of 3 samples. * indicates significant difference between 
control and Sb(III) exposure groups at p<0.05. 
 
 
Fig. 8. GSH concentration in HEK-293 cells after 24h 25 μM BSO treatment. * indicates 
significant difference between control and BSO treatment group at p<0.05 
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Role of GSH on antimony detoxification in HEK293 cells 
The GSH concentration in HEK293 cells was significantly decreased from 222.6 
μM to 58.9 μM 24 h after the BSO treatment (Fig.8). 
Regardless of the amount of GSH in the cell, there is no significant difference in 
the toxicity of the cell from 0 to 100 μM Sb (III), and the cell viability is above 80% 
(Fig.9). Beyond 200 μM Sb (III), the BSO group became more susceptible to Sb (III) 
than the control. Although no toxic effects was observed in the control at the Sb 
concentration of 500 μM, almost BSO-treated cells died. Indicating that GSH seemed 
to be one of key factors to protect cells against Sb (III) toxicity.  
 
Fig. 9. Viability of HEK293 cells after 24 hours exposure to Sb (III). * indicates significant 
difference between control and BSO treatment group at p<0.05 
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Determination of Sb in HEK293 cells by ICP-MS 
 The Sb concentration in the cells was 176 ng / 106 cells after the cells were exposed 
to 100μM Sb (III) for 24 hours. The Sb concentration in the cells was 890 ng / 106 cells 
by the GSH depletion. These results indicated that GSH seemed to play a role to efflux 
Sb from the cells. 
 
Fig. 10. Sb concentration in hek-293 cells. * indicates significant difference between 
control and Sb(III) exposure groups at p<0.05 
 
Evaluation of antimony methylation by AS3MT 
The upper elution profile indicates the result of the negative control without AS3MT, 
and the lower is the result with AS3MT (Fig.11). There were no apparent changes in 
both elution profiles. This result indicated that AS3MT dose not contribute to transform 
inorganic Sb to methylated form. 
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Fig. 11. Elution profiles of Sb reacted with AS3MT by LC-ICP-MS. column: PRP-
X100; buffer: 50 mM ammonium acetate, pH 6.5; flow rate: 0.8mL/min 
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Discussion 
ATP binding cassette transporters, ABC transports consist of various types on cell 
membrane. All eukaryotic ABC transporters act as efflux pumps. ABCC1 and ABCC2 
are known to play the role of arsenic and GSH conjugates in transporting arsenic out of 
cells (Pharmacology et al., 1999; Roggenbeck et al., 2016). The increased expression 
of ABCC2 seems to be a reasonable response to Sb(III) exposure, because Sb(III) is 
excreted through ABCC2 after GSH conjugate. ABCC1 and ABCC2 are expressed in 
basolateral (blood) and apical (urine) sides, respectively.  ABCC2 is more significant 
in the antimony metabolism of kidney cells in terms of detoxification. It is reasonable 
that ABCC2 was significantly induced but ABCC1 was not by the antimony exposure. 
MDR1 is responsible for effluxing inorganic trivalent arsenic, and the expression of 
MDR1 does not increase significantly by the antimony exposure, indicating that MDR1 
is not the main pathway for Sb to be effluxed. AQP7 plays a role of influx pump in the 
metabolism of arsenic. AQP7 expression did not decrease significantly after the 
exposure, suggesting that AQP7 did not act as an influx pump for antimony in the cells. 
ABCC2 transporter is mainly distributed in the luminal membrane of hepatocytes 
and the luminal side of proximal tubule cells (Kusuhara and Sugiyama, 2002). ABCC2 
transporter can recognize and transport arsenic (Masuda et al., 1997), and it also plays 
an important role for recognition and transportation of antimony. In another words, 
ABCC2 plays an important role in the accumulation and metabolism of inorganic 
trivalent antimony in the liver and kidney of rodent animals like rats and hamsters. 
 38 
The cytotoxicity of antimony was increased greatly with the decrease of GSH. In the 
control group, when the Sb(III) concentration was 5000 μM, the cell viability decreased 
to less than 10%, and the cell viability was more than 80% at 500 μM. After the GSH 
content in the cells was reduced, the cell viability was reduced to 5% at a concentration 
of 500 μM. GSH concentration in cells was reduced by the BSO treatment. The 
concentration of antimony in cells increased to five-times higher than the cells without 
the BSO treatment. This proved that in HEK293, that GSH was required to form the 
GSH-Sb(III) conjugate to excrete Sb from the cells. These mechanisms for the Sb 
excretion was coincident with the efflux mechanism of arsenic by ABCC2.  
AS3MT participates in the methylation reaction of arsenic and promotes the 
metabolism of inorganic arsenic (Lin et al., 2002). In the metabolism process of 
inorganic arsenic, trivalent monomethylarsenous acid (MMAIII) and dimethylarsenous 
acid (DMAIII) can be produced. These organic arsenic compounds have strong 
cytotoxicity and genotoxicity, and are much more toxic than inorganic inorganic AsIII 
(Lin et al., 2002; Sakurai et al., 2002). AS3MT plays an important role in the 
methylation of arsenic. The methylation in mammals by AS3MT progresses step-by-
step, namely, inorganic arsenic is methylated to demethylated form via 
monomethylated form. From the results in Fig. 11, the product composition of the 
antimony compound was the same regardless in the presence or absence of AS3MT 
suggesting that AS3MT was not involved in the methylation of antimony. Thus, 
antimony is not methylated in the cells, and non-methylated antimony is conjugated to 
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GSH for the excretion. In the previous study by our laboratory, no apparent methylated 
antimony compounds were detected in urine of rats administratered with inorganic 
antimon (Kobayashi et al., 2003). My observation is coincident with the previous study. 
Consequently, no methylation is the specific metabolism of antimony. 
Although antimony and arsenic accumulations have species differences in the RBCs 
rodents, it is different between organs and blood. Inorganic antimony is not metabolized 
in a methylated method, so less toxic methylated antimony is not formed during the 
metabolism. But it is metabolized by combining with GSH to form a chelate. Therefore, 
in the development of treatment for Leishmaniasis and drug resistance research, it can 
be considered as a starting point in combination with GSH to improve the treatment 
effect by reducing oxidative stress in patients. 
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CONCLUSIONS 
There are species differences in the Sb metabolism between two rodents. The Sb 
accumulation in hamster RBCs is less than that in rats, and there is no significant 
difference in the Sb amount excreted in urine suggesting that Sb is more toxic to 
hamsters than rats. In future animal experiments related to Sb toxicity, the species 
differences should be considered. There are also differences in the metabolism of 
trivalent and pentavalent Sb compounds. Trivalent Sb showed greater accumulation 
than pentavalent Sb in rat RBCs. 
Among the arsenic-related transporters, ABCC2 is most apparently involved in the 
Sb transport. The Sb transport by ABCC2 required that Sb was bound to GSH in 
HEK293 cells. GSH plays an important role in the Sb resistance of cells. The Sb-GSH 
complex is needed for the Sb efflux although arsenic -GSH complex is mainly used as 
a substrate for the arsenic methylation. Namely, Sb is excreted as a non-methylated 
from. 
  
 41 
ACKNOWLEDGMENTS 
My deepest gratitude goes first and foremost to Professor Yasumitsu Ogra, for his 
constant encouragement and guidance. He has walked me through all the stages of the 
writing of this thesis. Without his consistent and illuminating instruction, this thesis 
could not have reached its present form. 
I am also greatly indebted to the professors and teachers at the Laboratory of 
Toxicology and Environment Health: Associate Professor Noriyuki Suzuki, Assistant 
Professor Yu-ki Tanaka, who have instructed and helped me a lot in the past three years. 
I also owe my sincere gratitude to all members of the Laboratory of Toxicology and 
Environment Health who gave me their help and time in listening to me and helping 
me work out my problems during the difficult course of the thesis. 
Last my thanks would go to my beloved family and my friends for their loving 
considerations and great confidence in me all through these years. 
  
 42 
REFERENCES 
Croft, S.L., Sundar, S., and Fairlamb, A.H. (2006). Drug Resistance in Leishmaniasis. 
19, 111–126. 
Decuypere, S., Rijal, S., Yardley, V., Doncker, S. De, Laurent, T., and Khanal, B. 
(2005). Gene Expression Analysis of the Mechanism of Natural Sb ( V ) Resistance in 
Leishmania donovani Isolates from Nepal. 49, 4616–4621. 
Gazanion, E., Manoir, D., Sollelis, L., Sterkers, Y., and Ba, A. (2019). A single amino 
acid substitution ( H451Y ) in Leishmania calcium-dependent kinase SCAMK confers 
high tolerance and resistance to antimony. J Antimicrob. Chemother 14, 3231–3239. 
Haldar, A.K., Sen, P., and Roy, S. (2011). Use of Antimony in the Treatment of 
Leishmaniasis : Current Status and Future Directions. Mol. Biol. Int. 2011, 23. 
Hayakawa, T., Kobayashi, Æ.Y., and Cui, Æ.X. (2005). A new metabolic pathway of 
arsenite : arsenic – glutathione complexes are substrates for human arsenic 
methyltransferase Cyt19. Arch Toxicol 79, 183–191. 
He, M., Wang, X., Wu, F., and Fu, Z. (2012). Science of the Total Environment 
Antimony pollution in China. Sci. Total Environ. 421–422, 41–50. 
He, M., Wang, N., Long, X., Zhang, C., Ma, C., Zhong, Q., Wang, A., Wang, Y., 
Pervaiz, A., and Shan, J. (2018). ScienceDirect Antimony speciation in the 
environment : Recent advances in understanding the biogeochemical processes and 
ecological effects. J. Environ. Sci. 75, 14–39. 
Kobayashi, A., Takahashi, T., Sugai, S., and Miyakawa, Y. (2003). URINARY 
EXCRETION OF OXIDATIVE METABOLITES OF BILIRUBIN IN 
FENOFIBRATE-TREATED RATS. J. Toxicol. Sci. 28, 71–75. 
Kusuhara, H., and Sugiyama, Y. (2002). Role of transporters in the tissue-selective 
distribution and elimination of drugs : transporters in the liver , small intestine , brain 
and kidney. J. Control. Release 78, 43–54. 
 43 
Lin, S., Shi, Q., Nix, F.B., Styblo, M., Beck, M.A., Herbin-davis, K.M., Hall, L.L., 
Simeonsson, J.B., Thomas, D.J., Carolina, N., et al. (2002). A Novel S -Adenosyl- L -
methionine : Arsenic ( III ) Methyltransferase from Rat Liver Cytosol *. J. Biol. 
Chem. 277, 10795–10803. 
Lu, M., Wang, H., Li, X., Lu, X., Cullen, W.R., Arnold, L.L., Cohen, S.M., and Le, 
X.C. (2004). Evidence of Hemoglobin Binding to Arsenic as a Basis for the 
Accumulation of Arsenic in Rat Blood. Chem. Res. Toxicol. 17, 1733–1742. 
Masuda, M., Yuji, I., Yamazaki, M., Nishigaki, R., Kato, Y., Ni, K., Suzuki, H., and 
Sugiyama, Y. (1997). Methotrexate Is Excreted into the Bile by Canalicular 
Multispecific Organic Anion Transporter in Rats. Cancer Res. 57, 3–8. 
Mengchang, H. (2005). Distribution , Speciation , Toxicity and Bioavailability. Prog. 
Chem. 16, 1–5. 
Mishra M, Biswas UK, Jha DN, K.A. (1992). Amphotericin versus pentamidine in 
antimony-unresponsive kala-azar. Lancet 340, 1256–1257. 
Naranmandura, H., Suzuki, N., and Suzuki, K.T. (2006). Trivalent arsenicals are 
bound to proteins during reductive methylation. Chem. Res. Toxicol. 19, 1010–1018. 
Naranmandura, H., Suzuki, N., Iwata, K., Hirano, S., and Suzuki, K.T. (2007). 
Arsenic Metabolism and Thioarsenicals in Hamsters and Rats. Chem. Res. Toxicol. 
20, 616–624. 
Pharmacology, D., A, T.R.A.M.H. Van, Biochemistry, J.B.K., and O, C.P.C.H. Van 
(1999). Mechanisms and Interaction of Vinblastine and Reduced Glutathione 
Transport in Membrane Vesicles by the Rabbit Multidrug Resistance Protein Mrp2 
Expressed in Insect Cells. 719, 714–719. 
Roggenbeck, B.A., Banerjee, M., and Leslie, E.M. (2016). Cellular arsenic transport 
pathways in mammals. J. Environ. Sci. 9, 38–58. 
Sakurai, T., Qu, W., Sakurai, M.H., and Waalkes, M.P. (2002). A Major Human 
Arsenic Metabolite , Dimethylarsinic Acid , Requires Reduced Glutathione To Induce 
Apoptosis. Chem. Res. Toxicol. 15, 629–637. 
 44 
Shiobara, Y., Ogra, Y., and Suzuki, K.T. (2001). Animal Species Difference in the 
Uptake of Dimethylarsinous Acid ( DMA III ) by Red Blood Cells. Chem. Res. 
Toxicol. 14, 1446–1452. 
Sundar, S., and Chakravarty, J. (2010). Antimony Toxicity. Environ. Res. Public 
Heal. 7, 4267–4277. 
Sundar, S., and Goyal, N. (2007). Molecular mechanisms of antimony resistance in 
Leishmania. J. Med. Microbiol. 56, 143–153. 
Ye, L., Qiu, S., Li, X., Jiang, Y., and Jing, C. (2018). Science of the Total 
Environment Antimony exposure and speciation in human biomarkers near an active 
mining area in Hunan , China. Sci. Total Environ. 640–641, 1–8. 
 
  
 45 
LIST OF PUBLICATION 
Zhou, Q., Tanaka. Y., Suzuki, N., and Ogra, Y. Species difference in antimony and 
arsenic metabolism between hamster and rat after administration of tri- or pentavalent 
inorganic antimony. Fundam. Toxicol. Sci. 6: 181-185 (2019) 
  
 46 
Judgement of the possibility for application to Doctoral Thesis performed by 
Doctoral Dissertation Committee consisting of the following professors. 
 
Professor Kousei Itoh, Ph.D. 
  (Graduate School of Pharmaceutical Sciences, Chiba University) 
Professor Motoyuki Itoh, Ph.D. 
 (Graduate School of Pharmaceutical Sciences, Chiba University) 
Professor Daisuke Nakajima, Ph.D. 
(Visiting Professor, Graduate School of Pharmaceutical Sciences, Chiba 
University / National Institute for Environmental Studies) 
Professor Narenmandula, Ph.D. 
 (School of Medicine, Zhejiang University) 
 
